Welcure Drugs & Pharmaceuticals share news and announcements

BSE: 524661Pharmaceuticals & BiotechnologySmall Cap

₹0.18₹0.02 (10.00%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹0.20.

52-week range of traded prices to 23 Oct 2026

₹0.17Low, 23 Oct 2026₹0.72High, 23 Oct 2025

Market cap: ₹22 Cr3,646th largest listed
P/E: No recent results
P/B: No recent results
Dividend yield: Nonein the last 12 months
Volume, BSE: 76,25,873

Welcure Drugs & Pharmaceuticals share news and announcements

550 announcements, routine notices left out, newest first. Page 5 of 11.

Sep 2023
Aug 2023
- 29 Aug · Business
  We would like to inform that the Company has entered into Tripartite Agreement on 22nd August, 2023 with Skyline Financial .... (opens in a new tab)
- 14 Aug · Submission Of Disclosure Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
  Regulation 32 of SEBI (LODR) regulations, 2015 is not applicable on our company for the Quarter ended June 30, 2023. (opens in a new tab)
- 14 Aug · Results
  30 of SEBI(LODR) Regulation, 2015, un-audited financial results for the quarter ended June 30, 2023 along with Limited Review Report. (opens in a new tab)
- 14 Aug · Results
  30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), .... (opens in a new tab)
- 4 Aug · Board meeting
  Meeting on 14 Aug 2023: quarterly results
- 2 Aug · Announcement under Regulation 30 (LODR)-Change in RTA
  We wish to inform that the Registrar and Share Transfer Agent (RTA) of the Company has been changed from M/S Link Intime .... (opens in a new tab)
- 1 Aug · Revised Outcome Of Board Of Directors Meeting- 11Th July, 2023
  We wish to inform you that the Board of Directors of the Company in their meeting held on Tuesday, 11th July, 2023 at 3:00 p.m and concluded at 6:30 p.m inter-alia, approved the following: .... (opens in a new tab)
Jul 2023
- 11 Jul · Compliance As Per Regulation 23(9) Of SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015.
  Submission of Compliance as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (opens in a new tab)
- 11 Jul · Disclosure Under Regulation 32 Of SEBI (Listing Obligation And Disclosure Requirements ) Regulations, 2015
  Submission of Disclosure under Regulation 32 of SEBI (Lising Obligations and Disclosure Requirements) Regulations, 2015 (opens in a new tab)
- 11 Jul · Results
  Audited Financial Results of the company for the year ended 31st March, 2023 (opens in a new tab)
- 11 Jul · Results
  Audited Financial Results together with Auditor's Report on such Audited Financial Results for the quarter and Year ended March 31, 2023. (opens in a new tab)
- 5 Jul · Board meeting
  Meeting on 11 Jul 2023: audited results and quarterly results
- 5 Jul · Dividend
  With reference to the above captioned subject, we are hereby submitting the Undertaking for confirming the payment of interest/dividend/principal obligations for non-convertible securities .... (opens in a new tab)
May 2023
- 23 May · Board meeting
  Meeting on 29 May 2023: audited results and quarterly results
Apr 2023
- 11 Apr · Submission Of Compliance Certificate As Per Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
  We are hereby submitting the Compliance Certificate under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended 31st March, 2023. (opens in a new tab)
- 10 Apr · Submission Of Compliances As SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
  We are hereby submitting the Certificate under Regulation 40(9) of the SEBI (LODR), Regulations 2015 for the year ended 31st March, 2023 issued by M/s. V Kumar & Associates, New Delhi. (opens in a new tab)
- 7 Apr · Dividend
  With reference to the above captioned subject, we are hereby submitting the Undertaking for confirming the payment of interest/dividend/principal obligations for non-convertible securities .... (opens in a new tab)
Mar 2023
- 10 Mar · Intimation Pursuant To Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations") And Amendment Thereto.
  This is to inform that, the Company has submitted the application seeking for reclassification of the 'Promoters and Promoter Group' to the BSE Limited in accordance with Regulation 31A .... (opens in a new tab)
Feb 2023
- 15 Feb · Submission Of Disclosure Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
  With reference to the above subject, the provision of the Regulation 32 of SEBI (LODR) Regulations,2015, the Statement of Deviation or Variation for proceeds of public issue, rights issue, .... (opens in a new tab)
- 14 Feb · Intimation Pursuant To Regulation 31A Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015-Reclassification From Promoter Group To Public Category
  We would like to inform that the Board of Directors at its meeting held on 14th February, 2023, has considered and approved the requests received from the below promoters, classified as .... (opens in a new tab)
- 14 Feb · Outcome Of Board Of Directors Meeting- 14Thfebruary, 2023
  30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), .... (opens in a new tab)
- 14 Feb · Board meeting
  30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), .... (opens in a new tab)
- 13 Feb · Board meeting
  WELCURE DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 ,inter alia, to consider and approve With reference .... (opens in a new tab)
- 13 Feb · Board meeting
  WELCURE DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 ,inter alia, to consider and approve With reference .... (opens in a new tab)
- 1 Feb · Board meeting
  Meeting on 14 Feb 2023: quarterly results
Jan 2023
- 30 Jan · Intimation Of Website Address Of The Company
  Dear Sir/Madam, We wish to inform you that the official website of the Company is www.welcuredrugs.com We request you to kindly take the same on your record and update the same in .... (opens in a new tab)
- 17 Jan · INTIMATION OF RECEIPT OF A REQUEST LETTER FROM THE PROMOTER OF THE COMPANY FOR RE-CLASSIFICATION TO 'PUBLIC' CATEGORY FROM 'PROMOTER' CATEGORY
  This is to inform you that the Company has received a letter dated 16th January, 2023from Mr. Dharam Chand Jain, Promoter of the Company, seeking re-classification of its name from the .... (opens in a new tab)
Nov 2022
- 29 Nov · Board meeting
  With reference to the above captioned subject, it is to inform you that following are the outcome of the Board Meeting held today i.e. on Tuesday, 29th November, 2022 at 04.00P.M and concluded .... (opens in a new tab)
- 24 Nov · Board meeting
  Meeting on 29 Nov 2022: increase in authorised capital and preferential issue of shares
- 24 Nov · Board meeting
  WELCURE DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/11/2022 ,inter alia, to consider and approve With reference .... (opens in a new tab)
Oct 2022
- 22 Oct · Management
  Intimation for appointment of Company Secretary & Compliance officer of the Company (opens in a new tab)
- 8 Oct · Results
  This is with reference to our letter dated 08.10.2022 submitted for un-audited financial results for the quarter and half year ended 30th September, 2022; we hereby submit the rectified .... (opens in a new tab)
- 8 Oct · Management
  Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the Stock Exchange that the Company has received .... (opens in a new tab)
- 8 Oct · Management
  We wish to inform you that Mr. Dharam Chand Jain (DIN: 00323379) and Ms. Mitashi Bisaria .... (opens in a new tab)
- 8 Oct · Management
  Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the Stock Exchange that the Company has received .... (opens in a new tab)
- 8 Oct · Announcement under Regulation 30 (LODR)-Change in Registered Office Address
  We wish to inform you that the Board of Directors of the Company at their meeting held on October 08, 2022 have accorded their consent to shift the registered office of the Company from .... (opens in a new tab)
- 8 Oct · Results
  Pursuant to the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company .... (opens in a new tab)
- 8 Oct · Board meeting
  30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), .... (opens in a new tab)
- 3 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
  No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
- 3 Oct · Board meeting
  Meeting on 8 Oct 2022: quarterly results
- 1 Oct · Board meeting
  WELCURE DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/10/2022 ,inter alia, to consider and approve the Un-Audited .... (opens in a new tab)
Sep 2022
- 20 Sep · Disclosure
  Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Lata Jain (opens in a new tab)
- 15 Sep · Disclosure
  Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Madhudevi S Bucha (opens in a new tab)
- 12 Sep · Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
  6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, Mr. Sandeep Jain, Immediate Relative had send Form C under the above .... (opens in a new tab)
- 12 Sep · Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
  6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, Mr. Dharam Chand Jain, Promoter of the Company had send Form C under .... (opens in a new tab)

Welcure Drugs & Pharmaceuticals share news and announcements

Sep 2023

Aug 2023

Jul 2023

May 2023

Apr 2023

Mar 2023

Feb 2023

Jan 2023

Nov 2022

Oct 2022

Sep 2022